Sensei Biotherapeutics Closes Faeth Acquisition and Financing

The latest announcement is out from Sensei Biotherapeutics ( (SNSE) ).

On February 17, 2026, Sensei Biotherapeutics completed a stock-for-stock acquisition of Faeth Therapeutics, making Faeth a wholly owned subsidiary and adding its lead asset PIKTOR to Sensei’s oncology pipeline. The deal significantly reshapes the cap table, leaving pre-transaction Sensei holders with about 4.9% of the combined company on a fully diluted, as-converted basis, while former Faeth equityholders and new investors hold roughly 40.8% and 54.3%, respectively.

Concurrent with the acquisition, Sensei arranged a private placement of Series B non-voting convertible preferred stock expected to raise about $200 million, structured to convert into common stock subject to shareholder approval and ownership limits. The company also created the new Series B preferred class with limited voting rights but key protective provisions, and granted inducement equity awards, including a sizeable stock option package, to Faeth personnel as part of leadership changes that installed Faeth co-founder Anand Parikh as Sensei’s chief operating officer and a board director.

On February 17, 2026, Sensei’s board appointed Parikh as a Class I director and chief operating officer, while also adding Mr. Donenberg to the audit committee and amending retention agreements for senior executives Christopher Gerry and Josiah Craver. The equity and retention packages, along with more than 2.3 million option inducement awards to incoming Faeth employees, aim to secure management continuity and align incentives as the enlarged company advances PIKTOR through Phase 2 endometrial cancer and Phase 1b breast cancer milestones and completes its solnerstotug trial.

In connection with the merger and financing, Sensei filed a Certificate of Designation on February 17, 2026, establishing the terms of the Series B preferred stock, including dividend parity with common shares and restrictions on certain corporate actions without preferred holder approval. The automatic conversion feature, post-stockholder approval, and beneficial ownership caps are designed to manage dilution, maintain regulatory compliance and give institutional investors structural protections while concentrating strategic control of major transactions in the hands of preferred holders.

The most recent analyst rating on (SNSE) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.

Spark’s Take on SNSE Stock

According to Spark, TipRanks’ AI Analyst, SNSE is a Neutral.

The score is held down primarily by weak fundamentals—minimal/negative revenue, persistent losses, and ongoing cash burn with a shrinking equity base—implying continued financing risk. Technicals are a relative bright spot with price trading above key moving averages and positive MACD, but valuation remains constrained by negative earnings, and corporate events add uncertainty due to program discontinuation and strategic review.

To see Spark’s full report on SNSE stock, click here.

More about Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. is a Nasdaq-listed, clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. Following its acquisition of Faeth Therapeutics, Sensei’s lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer, alongside its ongoing Phase 1/2 trial of VISTA inhibitor solnerstotug.

Faeth Therapeutics, also a clinical-stage biotechnology company, develops multi-node therapies that target tumor metabolism and signaling. Its lead asset PIKTOR is an all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, and is being advanced across solid tumors including endometrial and breast cancer.

Average Trading Volume: 87,713

Technical Sentiment Signal: Sell

Current Market Cap: $11.47M

Learn more about SNSE stock on TipRanks’ Stock Analysis page.